Walk US

Walk US is the United States-based clinical and service network of Wandercraft, a French medical technology company specializing in self-balancing robotic exoskeletons. The company operates specialized neurorehabilitation centers, including flagship locations in New York City and Miami, which utilize the Atalante X exoskeleton for gait retraining and rehabilitation. Walk US serves as a critical partner for the evaluation, training, and commercial launch of Wandercraft's personal-use exoskeleton, Eve, which received FDA clearance in 2023. By providing structured training programs and clinical assessments, Walk US aims to improve mobility and independence for patients with severe walking impairments due to stroke, spinal cord injuries, and other neurological conditions.